Savara Inc. (YB4P.F)
Frankfurt · EUR · Healthcare · Biotechnology
€3.97 (+6.12%) as of
Key statistics
- Market cap
- 813.77M
- Forward P/E
- -11.68
- EPS (TTM)
- -0.5000
- Dividend yield
- 0.00%
- 52-week range
- 3.3600 – 5.9000
- Beta
- 0.20
- Profit margin
- 0.00%
- Volume
- 500.00
About Savara Inc.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Yardley, PA, United States
- Employees
- 70
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.